A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes

NCT01427699 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: T2-18C3 therapeutic antibody

Sponsor

Janssen Research & Development, LLC